Header5

The simple corporate scheme behind massive US Brand Drug Prices

My 7-year whistleblower effort
"People Before Profits"

Vast Patient and Taxpayer Harm

Massive U.S. Brand Drug Price Increases That Should Never Have Happened

5-to-10-Fold U.S. Price Increases for Many "Old" U.S. Blockbuster Brands

  • Insulins:  Sanofi’s Lantus, Eli Lilly’s Humulin and others
  • Cancer Drugs: Novartis’ Gleevec and many others
  • Multiple Sclerosis: Biogen’s Avonex, Teva’s Copaxone, Pfizer/Serono's Rebif and Bayer's Betaseron and others
  • Rheumatoid Arthritis: AbbVie’s Humira and Amgen’s Enbrel
  • Other major U.S brand drugs: Pfizer's Lyrica, Premarin and Viagra, Mylan's Epipen, Mallinckrodt's Acthar Gel, Martin Shkreli, Valeant Pharmaceuticals and many others
  • Oxycontin, other U.S. opioid brands and the U.S. opioid crisis

Severe Patient and Family Harm

  • Diabetics dying without insulin
  • U.S. multiple sclerosis patients facing 10-fold price increases
  • U.S. cancer patients and families struggling to afford $200-400,000/year therapies
  • Many other severely ill U.S. patients struggling with enormous drug costs and losing access to life-saving therapies
  • Severe financial distress – rising patient and family bankruptcies
  • Rising health insurance premiums, increased healthcare costs and deteriorating coverage for all Americans

Vast Public and Taxpayer Financial Harm

  • A shocking $175+ billion over the past decade-plus just for the 22 blockbuster drugs in these two Whistleblower cases
  • The largest healthcare Whistleblower cases in history, by a wide margin
  • An ongoing and escalating systemic scheme involving many other U.S. brand drugs
  • Widespread rising U.S. drug costs and public harm that never should have happened

MASSIVE PRICE INCREASES FOR "OLD" BLOCKBUSTER U.S. BRAND DRUGS LED TO EVEN HIGHER PRICES FOR NEWER BRAND DRUGS

Receive the Latest News

Your email is 100% safe.
Your privacy will be respected.
!
!
Something went wrong. Please check your entries and try again.
Scroll to Top